Cordon-Cardo C, Zhang Z F, Dalbagni G, Drobnjak M, Charytonowicz E, Hu S X, Xu H J, Reuter V E, Benedict W F
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Cancer Res. 1997 Apr 1;57(7):1217-21.
Altered patterns of p53 and pRB expression have been reported to be frequent events and to have prognostic significance in bladder cancer. To assess the potential adverse consequences of having altered patterns of both p53 and pRB proteins in patients with bladder neoplasms compared with having one or neither abnormality, we have studied a cohort of superficial transitional cell carcinomas of the urinary bladder by immunohistochemical analysis. The present study included 59 well-characterized superficial transitional cell carcinomas (Ta, n = 28; T1, n = 31) for which clinicopathological variables were available. Nuclear overexpression of p53 was identified in 22 cases (37%). A statistically significant association was observed between the p53-positive phenotype and disease progression (P < 0.001), as well as reduced survival (P < 0.001). Undetectable levels of pRB were observed in 11 cases (19%). Patients with a pRB-negative phenotype had a more frequent disease progression (P = 0.014) and decreased overall survival (P = 0.014). We also observed a significant association between altered p53 and undetectable pRB expression patterns (P = 0.001). Nine tumors showed both a p53-positive and a pRB-negative phenotype. There was an even more marked increase in progression (P = 0.00005) and decreased overall survival (P = 0.0004) in patients whose tumors had both alterations after controlling for tumor stage, tumor grade, and suspicion of vascular invasion. These data suggest that alterations of p53 and pRB have a cooperative negative effect on both progression and survival in primary bladder cancer. It may be postulated that aberrant p53 and pRB expression deregulates cell cycle control at the G1 checkpoint and engenders tumor cells with reduced response to programmed cell death. The imbalance produced by an enhanced proliferative activity and a decreased apoptotic rate may determine the aggressive clinical course of the bladder tumors harboring both p53 and pRB alterations.
据报道,p53和pRB表达模式的改变在膀胱癌中是常见事件,且具有预后意义。为了评估膀胱肿瘤患者中p53和pRB蛋白表达模式均改变与仅有其中一种异常或两者均无异常相比的潜在不良后果,我们通过免疫组化分析研究了一组膀胱浅表性移行细胞癌。本研究纳入了59例特征明确的膀胱浅表性移行细胞癌(Ta期,n = 28;T1期,n = 31),这些病例的临床病理变量均可用。22例(37%)病例中发现p53核过表达。p53阳性表型与疾病进展(P < 0.001)以及生存率降低(P < 0.001)之间存在统计学显著关联。11例(19%)病例中未检测到pRB水平。pRB阴性表型的患者疾病进展更频繁(P = 0.014),总生存率降低(P = 0.014)。我们还观察到p53改变与未检测到的pRB表达模式之间存在显著关联(P = 0.001)。9例肿瘤表现出p53阳性和pRB阴性表型。在控制肿瘤分期、肿瘤分级和血管侵犯怀疑因素后,肿瘤同时存在这两种改变的患者进展更为明显(P = 0.00005),总生存率降低(P = 0.0004)。这些数据表明,p53和pRB的改变对原发性膀胱癌的进展和生存具有协同负面影响。可以推测,异常的p53和pRB表达会在G1检查点失调细胞周期控制,并产生对程序性细胞死亡反应降低的肿瘤细胞。增殖活性增强和凋亡率降低所产生的失衡可能决定了同时存在p53和pRB改变的膀胱肿瘤的侵袭性临床病程。